IDO1 and neoplasm: Considering tumour mutations can result in immunogenic neo‐antigens, which have also been correlated with responsiveness to a more effective response to immune therapy, we analysed IDO1 expression with TMB status and grouped patients into IDO1‐high and IDO1‐low and analysed their TMB status.